Research Funding

Research in the Sikora Lab has been continuously supported by the National Institutes of Health (NIH) since 2015, principally through the National Institute of Allergy and Infectious Diseases (NIAID). We gratefully acknowledge past and present support from the following sources.

Current Funding

Proteomics-driven reverse vaccinology for gonorrhea — National Institute of Allergy and Infectious Diseases (NIAID), R01. Principal Investigator (Sikora). Award 2R01AI117235. 2022–2027.

Completed Support

Therapeutic formulation and delivery of a lipid-nanoparticle messenger RNA (mRNA) prototype vaccine against gonorrhea — Oregon State University Advantage Accelerator. Co-Principal Investigator (with Sahay). 2021–2022.

Bio-engineering full-length gonococcal lipoproteins with virus-like particles — Oregon State University Advantage Accelerator. Principal Investigator (Sikora). 2020–2021.

Proteomics and Outer Membrane Vesicles Core — National Institute of Allergy and Infectious Diseases (NIAID), U19. Core Leader (Program Principal Investigator: Jerse). Award U19AI144180. 2019–2024.

Nanodisc-displayed protein vaccines — National Institute of Allergy and Infectious Diseases (NIAID), U19. Project Leader (Program Principal Investigator: Jerse). Award U19AI144180. 2019–2024.

Proteomics-driven reverse vaccinology for gonorrhea — National Institute of Allergy and Infectious Diseases (NIAID), R01. Principal Investigator (Sikora). Award R01AI117235. 2015–2020. (Initial award; renewed — see Current Funding.)

Gut microbiota mediates the interplay between immunity and glucose metabolism — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), R01. Collaborator (Principal Investigator: Shulzhenko). Award R01DK103761. 2015–2020.

Fragment-based drug discovery toward inhibitors of the nitrite reductase AniA for the treatment of gonorrhea — Medical Research Foundation of Oregon, New Investigator Grant. Co-Principal Investigator (Principal Investigator: Jones). 2015–2017.

Targeting anaerobic respiration for the development of new therapeutics against gonorrhea — Oregon State University College of Pharmacy Pilot Grant. Principal Investigator (Sikora). 2014–2015.

Small molecule inhibitors of the essential bacterial Obg proteins — Oregon State University College of Pharmacy Pilot Grant. Principal Investigator (Sikora). 2014–2015.

NGC Chromatography System — Oregon State University Research Equipment Reserve Fund (Equipment Grant). Principal Investigator (Sikora). 2014.

Elicitation of antibiotic natural products in multispecies cultures of deep-sea vent-derived microorganisms — Oregon Sea Grant. Co-Principal Investigator (Principal Investigator: McPhail). 2013–2015.

Targeted identification of anti-gonococcal and anti-chlamydial compounds — Oregon State University Division Grant. Principal Investigator (Sikora; Co-Principal Investigators: Rockey, McPhail). 2013–2014.

Targeting the type II secretion system for natural product treatments against plant-pathogenic bacteria — Agricultural Research Foundation. Principal Investigator (Sikora). 2012–2014.

High-throughput proteomic approaches to discover novel drug targets in Neisseria gonorrhoeae — Medical Research Foundation of Oregon, New Investigator Grant. Principal Investigator (Sikora). 2012–2013.

MultiFlow Microplate Dispenser — Oregon State University Research Equipment Reserve Fund (Equipment Grant). Principal Investigator (Sikora). 2012.